Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Carcinoma, Renal Cell 71Carcinoma, Hepatocellular 26Prostatic Neoplasms 22Neoplasm Metastasis 19Neoplasms 18Carcinoma, Non-Small-Cell Lung 16Kidney Neoplasms 14Osteosarcoma 9Neuroendocrine Tumors 9Colorectal Neoplasms 9Carcinoma, Transitional Cell 9Carcinoma, Medullary 9Sarcoma 8Urinary Bladder Neoplasms 7Sarcoma, Ewing 7Melanoma 7Breast Neoplasms 7Brain Neoplasms 7Thyroid Neoplasms 6Ovarian Neoplasms 6Clear-cell metastatic renal cell carcinoma 6Recurrence 5Pancreatic Neoplasms 5Lung Neoplasms 5Carcinoma 5Urethral Neoplasms 4Triple Negative Breast Neoplasms 4Multiple Myeloma 4Liver Neoplasms 4Thyroid Cancer, Papillary 3

Interventions

Adalimumab 19Etanercept 16Methotrexate 11Infliximab 8tocilizumab 7Rituximab 7golimumab 6Abatacept 6tofacitinib 5Tumor Necrosis Factor Inhibitors 5olokizumab 4Certolizumab Pegol 4Antirheumatic Agents 3Saline Solution 2RC-18 2Nivolumab 2Leflunomide 2veltuzumab 1upadacitinib 1secukinumab 1sarilumab 1mavrilimumab 1entecavir 1cabozantinib 1baricitinib 1andecaliximab 1Vitamin D 1Vaccines 1TACI receptor-IgG Fc fragment fusion protein 1Syringes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Arthritis, Rheumatoid × cabozantinib × Clear all
NCT03816345 2026-05-13

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

National Cancer Institute (NCI)

Phase 1 Recruiting
300 enrolled
Other hematologic neoplasm

Arthritis, Rheumatoid, Autoimmune Diseases, Colitis, Ulcerative, Crohn Disease, Dermatomyositis, Lupus Erythematosus, Systemic, Multiple Sclerosis, Psoriasis, Scleroderma, Systemic, Sjogren's Syndrome, Inflammatory Bowel Diseases, Arthritis, Psoriatic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡